November 20th, 2006
Introgen’s NPRL2: A Novel Nanoparticle Tumor Supressor Gene Showing Promise in Reducing Tumor Growth and Reversing Resistance to Cisplatin
In some types of cancer (testicular, bladder, lung, oesophageal, stomach, ovarian) the chemotherapy drug cisplatin is one of the ever present component.
So imagine if the cancer patient develops resistance to cisplatin? No treatment effect = not getting better.
Introgen Theapeutics, Inc. (a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for […]
Recent Comments